( mma (PPAR-gamma) agonist (e.g....)Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes,Health

mma (PPAR-gamma) agonist (e.g., thiazolidinediones) when the single agent does not provide adequate glycemic control. (1.2) Important Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes mellitus (type 1 diabetes) or for the treatment of diabetic ketoacidosis. (1.3) DOSAGE AND ADMINISTRATION The recommended dose of JANUVIA is 100 mg once daily as monotherapy or as combination therapy with metformin or a PPAR-gamma agonist (e.g., thiazolidinediones). (2.1) JANUVIA can be taken with or without food. (2.1) Dosage Adjustment in Patients With Moderate, Severe and End Stage Renal Disease (ESRD) (2.2) ---------------------------------------------------------------------- 50 mg once daily 25 mg once daily ---------------------------------------------------------------------- Moderate Severe and ESRD CrCl greater than or equal to 30 CrCl less than 30 mL/min to less than 50 mL/min -Serum Cr levels (mg/dL) -Serum Cr levels (mg/dL) Men: greater than 1.7 - Men: greater than 3.0; less than or equal to 3.0; Women: greater than 1.5 - Women: greater than 2.5; less than or equal to 2.5 or on dialysis ---------------------------------------------------------------------- DOSAGE FORMS AND STRENGTHS Tablets: 100 mg, 50 mg, and 25 mg (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS A dosage adjustment is recommended in patients with moderate renal insufficiency and in patients with severe renal insufficiency or with ESRD requiring hemodialysis or peritoneal dialysis. Assessment of renal function is recommended prior to initiation of JANUVIA and periodically thereafter. Creatinine clearance can be estimated from serum creatinine using the Cockcroft-Gault formula. (2.2, 5)
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting